<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1099">
  <stage>Registered</stage>
  <submitdate>15/02/2006</submitdate>
  <approvaldate>23/02/2006</approvaldate>
  <actrnumber>ACTRN12606000078550</actrnumber>
  <trial_identification>
    <studytitle>Albendazole (oral) phase I</studytitle>
    <scientifictitle>A phase I (dose escalation) study of oral albendazole in patients with cancer refractory to conventional treatments to determine optimal dosing in cancer patients</scientifictitle>
    <utrn />
    <trialacronym>Albendazole</trialacronym>
    <secondaryid>TGA and St George Ethics Committee: ALB1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer refractory to conventional treatments</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Biliary tree (gall bladder and bile duct)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>An inter-patient dose escalation of oral albendazole according to the following schema:
   
-1. 400mg daily, day 1 - 7 every 28 days
1.  400mg twice daily, day 1 - 7 every 28 days
2. 400mg twice daily, day 1 - 14 every 28 days
3. 400mg 3 times per day, day 1 - 14 every 28 days
4. 800mg twice daily, day 1 - 14 every 28 days
5. 800mg twice daily, day 1 - 14 every 21 days
6. 1200mg morning 800mg afternoon, day 1 - 14 every 21 days
7. 1200mg twice daily, day 1 - 14 every 21 days

Dose will be increased if no dose limiting toxicity occurs. If one occurs, the cohort will be will be expanded to 6. If it recurs the dose limiting toxicity has been identified and no further dose increase will occur.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the maximum tolerated dose.  No further dose increase will occur once the maximum tolerated dose is determined.</outcome>
      <timepoint>The maximum tolerated dose will be defined as being one dose level below that at which a dose limiting toxicity appeared in 33% of a single cohort.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. To determine pharmacokinetics and safety profile.</outcome>
      <timepoint>Pharmacokinetics are measured during cycle 1. Safety is monitored through weekly visits to clinic where adverse events are identified.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. To determine preliminary efficacy through weekly measurement of relevant tumour markers.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologically or cytologically proven advanced or metastatic cancer2. Patients must have measurable (by imaging studies such as CT but not bone scan) or evaluable disease 3. Refractory to conventional treatments 4. A maximum of two previous systemic myelosuppressive chemotherapy regimens.5. Eastern Co-operative Oncology Group score (ECOG) 0-3 performance status.6. Patients with previously treated CNS (central nervous system) metastases are eligible, provided there is no clinical or radiological evidence of on-going CNS disease progression.7. Patients must have recovered from the reversible side effects of prior therapy.8. At least 3 weeks since prior chemotherapy (at least 6 weeks for agents known to be toxic to stem cells such as nitrosoureas, melphalan, or mitomycin).9. At least 2 weeks since any prior radiotherapy.  No more than 25% of bone marrow may have been irradiated in the past.10. Patients of all races and ethnic backgrounds are eligible.11. Adequate Haematological function12. Absolute neutrophils &gt; 1,500/mm3, platelets &gt; 100,000/mm3, 13. bilirubin &lt; 2x upper limit normal 14. Alanine amino transferase/aspartate amino transferase &lt; 10 x upper limit of normal, 15. Calculated creatinine clearance &gt; 60 mls/min.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients with unresolved ongoing infection requiring treatment.2. Decompensated liver disease with non malignant ascites or coagulopathy or encephalopathy3. Severe comorbidity at the discretion of the investigators4. Pregnancy or breast feeding mothers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>3 patients per dose cohort, expanded to 6 if dose limiting toxicity (DLT) occurs</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/09/2001</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>35</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St George Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Liver Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St George Hospital</ethicname>
      <ethicaddress>Kogarah</ethicaddress>
      <ethicapprovaldate>31/07/2001</ethicapprovaldate>
      <hrec>ver 1.5</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Private Hospital</ethicname>
      <ethicaddress>Kogarah</ethicaddress>
      <ethicapprovaldate>31/07/2001</ethicapprovaldate>
      <hrec>ver 1.5</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Matthew Links</name>
      <address>Clinical Trials Unit
Cancer Care Centre
St George Hospital
Kogarah NSW 2217</address>
      <phone>+61 2 93501935</phone>
      <fax>+61 2 93502960</fax>
      <email>matthew.links@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael Szwajcer</name>
      <address>Clinical Trials Unit
Cancer Care Centre
St George Hospital
Kogarah NSW 2217</address>
      <phone>+61 2 93503461</phone>
      <fax>+61 2 93502960</fax>
      <email>michael.szwajcer@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>